COVID-19 : is there evidence for the use of herbal medicines as adjuvant symptomatic therapy?
Saved in:
| Main Author: | |
|---|---|
| Publication Date: | 2020 |
| Other Authors: | , , , , , , , , |
| Format: | Article |
| Language: | eng |
| Source: | Repositório Institucional da UnB |
| Download full: | https://repositorio.unb.br/handle/10482/39687 https://doi.org/10.3389/fphar.2020.581840 |
Summary: | Background: Current recommendations for the self-management of SARS-Cov-2 disease (COVID-19) include self-isolation, rest, hydration, and the use of NSAID in case of high fever only. It is expected that many patients will add other symptomatic/adjuvant treatments, such as herbal medicines. Aims: To provide a benefits/risks assessment of selected herbal medicines traditionally indicated for “respiratory diseases” within the current frame of the COVID-19 pandemic as an adjuvant treatment. Method: The plant selection was primarily based on species listed by the WHO and EMA, but some other herbal remedies were considered due to their widespread use in respiratory conditions. Preclinical and clinical data on their efficacy and safety were collected from authoritative sources. The target population were adults with early and mild flu symptoms without underlying conditions. These were evaluated according to a modified PrOACT-URL method with paracetamol, ibuprofen, and codeine as reference drugs. The benefits/risks balance of the treatments was classified as positive, promising, negative, and unknown. Results: A total of 39 herbal medicines were identified as very likely to appeal to the COVID-19 patient. According to our method, the benefits/risks assessment of the herbal medicines was found to be positive in 5 cases (Althaea officinalis, Commiphora molmol, Glycyrrhiza glabra, Hedera helix, and Sambucus nigra), promising in 12 cases (Allium sativum, Andrographis paniculata, Echinacea angustifolia, Echinacea purpurea, Eucalyptus globulus essential oil, Justicia pectoralis, Magnolia officinalis, Mikania glomerata, Pelargonium sidoides, Pimpinella anisum, Salix sp, Zingiber officinale), and unknown for the rest. On the same grounds, only ibuprofen resulted promising, but we could not find compelling evidence to endorse the use of paracetamol and/or codeine. Conclusions: Our work suggests that several herbal medicines have safety margins superior to those of reference drugs and enough levels of evidence to start a clinical discussion about their potential use as adjuvants in the treatment of early/mild common flu in otherwise healthy adults within the context of COVID-19. While these herbal medicines will not cure or prevent the flu, they may both improve general patient well-being and offer them an opportunity to personalize the therapeutic approaches. |
| _version_ | 1871442651037827072 |
|---|---|
| author | Silveira, Dâmaris |
| author2 | Prieto-Garcia, Jose Maria Boylan, Fabio Estrada, Omar Fonseca-Bazzo, Yris Maria Jamal, Claudia Masrouah Batista, Pérola de Oliveira Magalhães Dias Pereira, Edson Oliveira Tomczyk, Michal Heinrich, Michael |
| author2_role | author author author author author author author author author |
| author_browse | Batista, Pérola de Oliveira Magalhães Dias Boylan, Fabio Estrada, Omar Fonseca-Bazzo, Yris Maria Heinrich, Michael Jamal, Claudia Masrouah Pereira, Edson Oliveira Prieto-Garcia, Jose Maria Silveira, Dâmaris Tomczyk, Michal |
| author_facet | Silveira, Dâmaris Prieto-Garcia, Jose Maria Boylan, Fabio Estrada, Omar Fonseca-Bazzo, Yris Maria Jamal, Claudia Masrouah Batista, Pérola de Oliveira Magalhães Dias Pereira, Edson Oliveira Tomczyk, Michal Heinrich, Michael |
| author_role | author |
| bitstream.checksum.fl_str_mv | b003fd59e39c069fe08794d42c8091dd ba54f8d1c5f5ec8df897ad678916c701 |
| bitstream.checksumAlgorithm.fl_str_mv | MD5 MD5 |
| bitstream.url.fl_str_mv | http://repositorio2.unb.br/jspui/bitstream/10482/39687/1/ARTIGO_Covid-19EvidenceUse.pdf http://repositorio2.unb.br/jspui/bitstream/10482/39687/2/license.txt |
| collection | Repositório Institucional da UnB |
| dc.contributor.author.fl_str_mv | Silveira, Dâmaris Prieto-Garcia, Jose Maria Boylan, Fabio Estrada, Omar Fonseca-Bazzo, Yris Maria Jamal, Claudia Masrouah Batista, Pérola de Oliveira Magalhães Dias Pereira, Edson Oliveira Tomczyk, Michal Heinrich, Michael |
| dc.date.accessioned.fl_str_mv | 2020-12-01T18:43:15Z |
| dc.date.available.fl_str_mv | 2020-12-01T18:43:15Z |
| dc.date.issued.fl_str_mv | 2020-09-23 |
| dc.identifier.citation.fl_str_mv | SILVEIRA, Dâmaris et al. COVID-19: is there evidence for the use of herbal medicines as adjuvant symptomatic therapy?. Frontiers in Pharmacology, v. 11, art. 581840, 23 set. 2020. DOI: https://doi.org/10.3389/fphar.2020.581840. Disponível em: https://www.frontiersin.org/articles/10.3389/fphar.2020.581840/full. Acesso em: 01 dez. 2020. |
| dc.identifier.doi.pt_BR.fl_str_mv | https://doi.org/10.3389/fphar.2020.581840 |
| dc.identifier.uri.fl_str_mv | https://repositorio.unb.br/handle/10482/39687 |
| dc.language.iso.fl_str_mv | eng |
| dc.publisher.none.fl_str_mv | Frontiers |
| dc.rights.driver.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.source.none.fl_str_mv | reponame:Repositório Institucional da UnB instname:Universidade de Brasília (UnB) instacron:UNB |
| dc.subject.keyword.pt_BR.fl_str_mv | Fitoterapia Covid-19 Avaliação benefício/risco Doenças respiratórias |
| dc.title.pt_BR.fl_str_mv | COVID-19 : is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? |
| dc.type.driver.fl_str_mv | info:eu-repo/semantics/article |
| dc.type.status.fl_str_mv | info:eu-repo/semantics/publishedVersion |
| description | Background: Current recommendations for the self-management of SARS-Cov-2 disease (COVID-19) include self-isolation, rest, hydration, and the use of NSAID in case of high fever only. It is expected that many patients will add other symptomatic/adjuvant treatments, such as herbal medicines. Aims: To provide a benefits/risks assessment of selected herbal medicines traditionally indicated for “respiratory diseases” within the current frame of the COVID-19 pandemic as an adjuvant treatment. Method: The plant selection was primarily based on species listed by the WHO and EMA, but some other herbal remedies were considered due to their widespread use in respiratory conditions. Preclinical and clinical data on their efficacy and safety were collected from authoritative sources. The target population were adults with early and mild flu symptoms without underlying conditions. These were evaluated according to a modified PrOACT-URL method with paracetamol, ibuprofen, and codeine as reference drugs. The benefits/risks balance of the treatments was classified as positive, promising, negative, and unknown. Results: A total of 39 herbal medicines were identified as very likely to appeal to the COVID-19 patient. According to our method, the benefits/risks assessment of the herbal medicines was found to be positive in 5 cases (Althaea officinalis, Commiphora molmol, Glycyrrhiza glabra, Hedera helix, and Sambucus nigra), promising in 12 cases (Allium sativum, Andrographis paniculata, Echinacea angustifolia, Echinacea purpurea, Eucalyptus globulus essential oil, Justicia pectoralis, Magnolia officinalis, Mikania glomerata, Pelargonium sidoides, Pimpinella anisum, Salix sp, Zingiber officinale), and unknown for the rest. On the same grounds, only ibuprofen resulted promising, but we could not find compelling evidence to endorse the use of paracetamol and/or codeine. Conclusions: Our work suggests that several herbal medicines have safety margins superior to those of reference drugs and enough levels of evidence to start a clinical discussion about their potential use as adjuvants in the treatment of early/mild common flu in otherwise healthy adults within the context of COVID-19. While these herbal medicines will not cure or prevent the flu, they may both improve general patient well-being and offer them an opportunity to personalize the therapeutic approaches. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | UNB_fcab20a5e4eaf17a023cffd6565a7e7e |
| identifier_str_mv | SILVEIRA, Dâmaris et al. COVID-19: is there evidence for the use of herbal medicines as adjuvant symptomatic therapy?. Frontiers in Pharmacology, v. 11, art. 581840, 23 set. 2020. DOI: https://doi.org/10.3389/fphar.2020.581840. Disponível em: https://www.frontiersin.org/articles/10.3389/fphar.2020.581840/full. Acesso em: 01 dez. 2020. |
| instacron_str | UNB |
| institution | UNB |
| instname_str | Universidade de Brasília (UnB) |
| language | eng |
| network_acronym_str | UNB |
| network_name_str | Repositório Institucional da UnB |
| oai_identifier_str | oai:repositorio.unb.br:10482/39687 |
| publishDate | 2020 |
| publishDateSort | 2020 |
| publisher.none.fl_str_mv | Frontiers |
| reponame_str | Repositório Institucional da UnB |
| repository.mail.fl_str_mv | repositorio@unb.br |
| repository.name.fl_str_mv | Repositório Institucional da UnB - Universidade de Brasília (UnB) |
| repository_id_str | |
| spelling | Silveira, DâmarisPrieto-Garcia, Jose MariaBoylan, FabioEstrada, OmarFonseca-Bazzo, Yris MariaJamal, Claudia MasrouahBatista, Pérola de Oliveira Magalhães DiasPereira, Edson OliveiraTomczyk, MichalHeinrich, Michael2020-12-01T18:43:15Z2020-12-01T18:43:15Z2020-09-23SILVEIRA, Dâmaris et al. COVID-19: is there evidence for the use of herbal medicines as adjuvant symptomatic therapy?. Frontiers in Pharmacology, v. 11, art. 581840, 23 set. 2020. DOI: https://doi.org/10.3389/fphar.2020.581840. Disponível em: https://www.frontiersin.org/articles/10.3389/fphar.2020.581840/full. Acesso em: 01 dez. 2020.https://repositorio.unb.br/handle/10482/39687https://doi.org/10.3389/fphar.2020.581840FrontiersCopyright © 2020 Silveira, Prieto-Garcia, Boylan, Estrada, Fonseca-Bazzo, Jamal, Magalhães, Pereira, Tomczyk and Heinrich. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.info:eu-repo/semantics/openAccessCOVID-19 : is there evidence for the use of herbal medicines as adjuvant symptomatic therapy?info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFitoterapiaCovid-19Avaliação benefício/riscoDoenças respiratóriasBackground: Current recommendations for the self-management of SARS-Cov-2 disease (COVID-19) include self-isolation, rest, hydration, and the use of NSAID in case of high fever only. It is expected that many patients will add other symptomatic/adjuvant treatments, such as herbal medicines. Aims: To provide a benefits/risks assessment of selected herbal medicines traditionally indicated for “respiratory diseases” within the current frame of the COVID-19 pandemic as an adjuvant treatment. Method: The plant selection was primarily based on species listed by the WHO and EMA, but some other herbal remedies were considered due to their widespread use in respiratory conditions. Preclinical and clinical data on their efficacy and safety were collected from authoritative sources. The target population were adults with early and mild flu symptoms without underlying conditions. These were evaluated according to a modified PrOACT-URL method with paracetamol, ibuprofen, and codeine as reference drugs. The benefits/risks balance of the treatments was classified as positive, promising, negative, and unknown. Results: A total of 39 herbal medicines were identified as very likely to appeal to the COVID-19 patient. According to our method, the benefits/risks assessment of the herbal medicines was found to be positive in 5 cases (Althaea officinalis, Commiphora molmol, Glycyrrhiza glabra, Hedera helix, and Sambucus nigra), promising in 12 cases (Allium sativum, Andrographis paniculata, Echinacea angustifolia, Echinacea purpurea, Eucalyptus globulus essential oil, Justicia pectoralis, Magnolia officinalis, Mikania glomerata, Pelargonium sidoides, Pimpinella anisum, Salix sp, Zingiber officinale), and unknown for the rest. On the same grounds, only ibuprofen resulted promising, but we could not find compelling evidence to endorse the use of paracetamol and/or codeine. Conclusions: Our work suggests that several herbal medicines have safety margins superior to those of reference drugs and enough levels of evidence to start a clinical discussion about their potential use as adjuvants in the treatment of early/mild common flu in otherwise healthy adults within the context of COVID-19. While these herbal medicines will not cure or prevent the flu, they may both improve general patient well-being and offer them an opportunity to personalize the therapeutic approaches.engreponame:Repositório Institucional da UnBinstname:Universidade de Brasília (UnB)instacron:UNBORIGINALARTIGO_Covid-19EvidenceUse.pdfARTIGO_Covid-19EvidenceUse.pdfapplication/pdf1086388http://repositorio2.unb.br/jspui/bitstream/10482/39687/1/ARTIGO_Covid-19EvidenceUse.pdfb003fd59e39c069fe08794d42c8091ddMD51open accessLICENSElicense.txtlicense.txttext/plain163http://repositorio2.unb.br/jspui/bitstream/10482/39687/2/license.txtba54f8d1c5f5ec8df897ad678916c701MD52open access10482/396872024-02-06 11:52:41.38open accessoai:repositorio.unb.br:10482/39687U3VibWlzc8OjbyBlZmV0aXZhZGEgcG9yIGludGVncmFudGUgZGEgZXF1aXBlIGRvIFJlcG9zaXTDs3JpbyBJbnN0aXR1Y2lvbmFsIGRhIFVuQiBkZSBhY29yZG8gY29tIGxpY2Vuw6dhIGNvbmNlZGlkYSBwZWxvIGF1dG9yIGUvb3UgZGV0ZW50b3IgZG9zIGRpcmVpdG9zIGF1dG9yYWlzLg==Repositório InstitucionalPUBhttps://repositorio.unb.br/oai/requestrepositorio@unb.bropendoar:2024-02-06T14:52:41Repositório Institucional da UnB - Universidade de Brasília (UnB) |
| spellingShingle | COVID-19 : is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? Silveira, Dâmaris Fitoterapia Covid-19 Avaliação benefício/risco Doenças respiratórias |
| status_str | publishedVersion |
| title | COVID-19 : is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? |
| title_full | COVID-19 : is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? |
| title_fullStr | COVID-19 : is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? |
| title_full_unstemmed | COVID-19 : is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? |
| title_short | COVID-19 : is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? |
| title_sort | COVID-19 : is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? |
| topic | Fitoterapia Covid-19 Avaliação benefício/risco Doenças respiratórias |
| url | https://repositorio.unb.br/handle/10482/39687 https://doi.org/10.3389/fphar.2020.581840 |